|
Search
Collections
Benchmarks
Upload document
Organization
Cortice Biosciences
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 clinical trial
Clinical trial
Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma
Status:
, Estimated PCD: 2024-11-01